Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: Negative influence of hepatitis C infection

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 107, Issue 7, 2013, Pages 432-437

  Farías, Adrián Alejandro ^a   Kremer, Luís Emilio ^b   Allende, Luís ^b   Díaz, María del Pilar ^a   Pisano, María Belen ^a   Contigiani, Marta Silvia ^a   Ré, Viviana Elizabeth ^a,c  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Universidad Nacional de Córdoba   (Argentina)

^c UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

Author keywords

CD4 cell counts; HAART; HIV HCV coinfection; Response to therapy; Viral load

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARGENTINA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COUNSELING; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROPREVALENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

CD4 CELL COUNTS; HAART; HIV/HCV COINFECTION; RESPONSE TO THERAPY; VIRAL LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84889055791     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trt043     Document Type: Article

References (43)

1. Operskalski E, Kovacs A. HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies. Curr HIV/AIDS Rep 2011;8:12-22.
2. Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-54.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-9.
4. Nachega JB, Stein DM, Lehman DA et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004;20:1053-56.
5. Brook G, Main J, Nelson M, et al. British HIVAssociation guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Medicine 2010;11:1-30.
6. Bica I, McGovern B, Dhar R, Stone D et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-97.
7. de Ledinghen V, Barreiro P, Foucher J et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008;15:427-33.
8. Lo Re V, Kostman J, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008;12:587-609.
9. Emery J, Pick N, Mills EJ, Cooper CL. Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviraltreated HIV-HCV coinfected patients. Patient Prefer Adherence 2010;13:97-103.
10. Emamzadeh-Fard S, Fard SE, Seyed Alinaghi S, Paydary K. Adherence to antiretroviral therapy and its determinants in HIV/AIDS patients: a review. Infect Disord Drug Targets 2012;12:346-56.
11. Hodder S, Arasteh K, De Wet J et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 2012;13:406-15.
12. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007;21:835-43.
13. Chen LF, Hoy J, Lewin SR. Ten years of highlyactive antiretroviral therapy for HIV infection. Med J Aus 2007;186:146-51.
14. Maqutu D, Zewotir T, North D et al. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr J AIDS Res 2010;9:117-24.
15. Fassio E, Schroder T, la Asociación Argentina para el Estudio de las Enfermedades del Hígado. Conclusiones del Consenso Argentino Hepatitis C 2007. Acta Gastroenterol Latinoam 2008;38:56-74.
16. Picchio GR, Baré PC, Descalzi VI et al. High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver Int 2006,26:660-65.
17. Ramadan A, Rossi L, Lura G et al. Prevalencia de infección por HCV en Rufino, Santa Fe [abstract]. Acta Gastroenterol Latinoam 2006;36 (Suppl 3):S69.
18. Mengarelli S, Correa G, Farias A et al. ¿Por que el virus de la Hepatitis Cen Cruz del Eje? [abstract]. Acta Gastroenterol Latinoam 2006;36 (Suppl 3):S68.
19. Mengarelli S, Kohn Ij, Correa G, et al. Circulación del Virus Cen la Provincia De Córdoba [abstract]. Acta Gastroenterol Latinoam 2006;36 (Suppl 3):S71.
20. Bessone F, Campodonico M, Fay Fet al. Elevada prevalencia de infección por HCV en personas mayores a 60 años en una localidad de 5800 habitantes [abstract]. Acta Gastroenterol Latinoam 2005;35 (Suppl 2):S59.
21. Fainboim H, González J, Fassio E et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat 1999;6:53-7.
22. Weissenbacher M, Rossi D, Radulich G et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis 2003;37:S348-52.
23. Remesar M, Gamba C, Kuperman S et al. Antibodies to hepatitis C and other viral markers in multi-transfused patients from Argentina. J Clin Virol 2005;34:S20-6.
24. Quarleri JF, Bolcic FM, Bouzas MB et al. HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors. Acta Gastroenterol Latinoam 2007;37:76-83.
25. Ré V, Gallego S, Farías A et al. Hepatitis C and HIV coinfection in central region of Argentina: prevalence, genotype characterization and risk factors. Enferm Infecc Microbiol Clin 2008;26:423-25.
26. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. World Health Organization; 2010. http://www.who.int/hiv/pub/arv/adult2010/en/index.html. [accessed 17 April 2013]
27. Ministry of Health of Argentina. Management of adult patients with HIV infection; 2011. http://www.who.int/hiv/pub/guidelines/argentina_art. pdf [accessed 17 April 2013]
28. Ré V, Lampe E, Yoshida CF et al. Hepatitis C virus genotypes in Cordoba, Argentina. Unexpected high prevalence of genotype 2. Medicina 2003;63:205-10.
29. Greub G, Ledergerber, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-05.
30. Soriano V, Martin-Carbonero L, Vispo E et al. Human immunodeficiency virus infection and viral hepatitis. Enferm Infecc Microbiol Clin 2011;29:691-701.
31. Rallón NI, Soriano V, Restrepo C et al. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr 2011;57:1-8.
32. Fuping G, Wei L, Yang H et al. Impact of hepatitis C virus coinfection on HAART in HIV-infected Individuals: multicentric observation cohort. J Acquir Immune Defic Syndr 2010;54:137-42.
33. Weis N, Lindhardt B, Kronborg G et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006;15:1481-87.
34. Thein HH, Yi Q, Dore GJ et al. Natural history of hepatitis Cvirus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-91.
35. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIVAIDS 2011;6:478-82.
36. Pulido F, Hill A, van Delft Y, Moecklinghoff C. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev 2012;14:124-31.
37. Cunningham WE, Markson LE, Andersen RM et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000;25:115-23.
38. Gebo KA, Fleishman JA, Conviser R et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96-103.
39. Furler MD,Einarson TR, Walmsley S, et al. Longitudinal trendsinantiretroviral use in a cohort of men and women in Ontario, Canada. AIDS Patient Care STDS 2006;20: 245-57.
40. Bacon MC, von Wyl V, Alden C et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005,12:1013-9.
41. Bratstein P, Zala Z, Yip B et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a populationbased HIV/AIDS treatment program. J Infect Dis 2006;193:259-68.
42. GESIDA/PNS/AEEH. Recomendaciones sobre tratamiento y manejo del paciente adulto coinfectado por VIH y virus de las hepatitis A, B Y C (Septiembre de 2009). Panel de expertos de Gesida, Secretaría del Plan Nacional sobre el Sida (SPNS) y Asociación Española para el Estudio del Hígado (AEEH). 2009; http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/coinfectadosHepatitis1Sep2009.pdf [accessed 17 April 2013].
43. SADI. Infectious Diseases Society of Argentina. Recommendations for monitoring and treatment. Infection by HIV/AIDS and its associated comorbidities. 2012; www.sadi.org.ar/files/SADI%202012.pdf [accessed 17 April 2013].